Galectin Therapeutics (GALT) Tops Q3 EPS by 5c

Galectin Therapeutics (NASDAQ: GALT) reported Q3 EPS of ($0.13), $0.05 better than the analyst estimate of ($0.18).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• Robinhood Ventures Fund II opens at $22.50, IPO at $25
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating